HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells

Cellular Signalling

Volumn 27, Issue 2, 2015, Pages 293-305

  Lee, Dae Hee ^a   Sung, Ki Sa ^c,d   Bartlett, David L ^a   Kwon, Yong Tae ^d   Lee, Yong J ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d Seoul National University College of Medicine   (South Korea)

Author keywords

Apoptosis; Heat shock protein 90 (HSP90); NVP AUY922; Tumor necrosis factor (TNF) related apoptosis inducing ligand (TRAIL)

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; JANUS KINASE 2; LUMINESPIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN MCL 1; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; STAT3 PROTEIN; 5-(2,4-DIHYDROXY-5-ISOPROPYLPHENYL)-4-(4-MORPHOLIN-4-YLMETHYLPHENYL)ISOXAZOLE-3-CARBOXYLIC ACID ETHYLAMIDE; CASPASE; HEAT SHOCK PROTEIN 90; ISOXAZOLE DERIVATIVE; JAK2 PROTEIN, HUMAN; MCL1 PROTEIN, HUMAN; RECOMBINANT PROTEIN; RESORCINOL DERIVATIVE; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL STRUCTURE; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PROTEIN CLEAVAGE; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; COLORECTAL TUMOR; DRUG EFFECTS; GENETICS; HCT116 CELL LINE; HT 29 CELL LINE; METABOLISM; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

APOPTOSIS; CASPASES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DOWN-REGULATION; DRUG SYNERGISM; HCT116 CELLS; HSP90 HEAT-SHOCK PROTEINS; HT29 CELLS; HUMANS; ISOXAZOLES; JANUS KINASE 2; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; RECOMBINANT PROTEINS; RESORCINOLS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84918813211     PISSN: 08986568     EISSN: 18733913     Source Type: Journal    
DOI: 10.1016/j.cellsig.2014.11.013     Document Type: Article

References (49)

1. Acheson A.G., Scholefield J.H. Br. J. Cancer 2008, 99(Suppl. 1):S33-S34.
2. Miura K., Satoh M., Kinouchi M., Yamamoto K., Hasegawa Y., Philchenkov A., Kakugawa Y., Fujiya T. Expert Opin. Drug Discov. 2014, 9:1087-1101.
3. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., Blackie C., Chang L., McMurtrey A.E., Hebert A., DeForge L., Koumenis I.L., Lewis D., Harris L., Bussiere J., Koeppen H., Shahrokh Z., Schwall R.H. J. Clin. Invest. 1999, 104:155-162.
4. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., Chin W., Jones J., Woodward A., Le T., Smith C., Smolak P., Goodwin R.G., Rauch C.T., Schuh J.C., Lynch D.H. Nat. Med. 1999, 5:157-163.
5. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K., Sutherland G.R., Smith T.D., Rauch C., Smith C.A., et al. Immunity 1995, 3:673-682.
6. Marsters S.A., Pitti R.M., Donahue C.J., Ruppert S., Bauer K.D., Ashkenazi A. Curr. Biol. 1996, 6:750-752.
7. El-Deiry W.S. Drug. Resist. Updat. 1999, 2:79-80.
8. Galligan L., Longley D.B., McEwan M., Wilson T.R., McLaughlin K., Johnston P.G. Mol. Cancer Ther. 2005, 4:2026-2036.
9. Xu L., Qu X., Zhang Y., Hu X., Yang X., Hou K., Teng Y., Zhang J., Sada K., Liu Y. FEBS Lett. 2009, 583:943-948.
10. Lee D.H., Kim D.W., Jung C.H., Lee Y.J., Park D. Toxicol. Appl. Pharmacol. 2014, 279:253-265.
11. Lee D.H., Kim D.W., Lee H.C., Lee J.H., Lee T.H. Biochem. Biophys. Res. Commun. 2014, 446:815-821.
12. Lee D.H., Rhee J.G., Lee Y.J. Br. J. Pharmacol. 2009, 157:1189-1202.
13. Grbovic O.M., Basso A.D., Sawai A., Ye Q., Friedlander P., Solit D., Rosen N. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:57-62.
14. Neckers L., Ivy S.P. Curr. Opin. Oncol. 2003, 15:419-424.
15. Kamal A., Thao L., Sensintaffar J., Zhang L., Boehm M.F., Fritz L.C., Burrows F.J. Nature 2003, 425:407-410.
16. Ciocca D.R., Clark G.M., Tandon A.K., Fuqua S.A., Welch W.J., McGuire W.L. J. Natl. Cancer Inst. 1993, 85:570-574.
17. Cornford P.A., Dodson A.R., Parsons K.F., Desmond A.D., Woolfenden A., Fordham M., Neoptolemos J.P., Ke Y., Foster C.S. Cancer Res. 2000, 60:7099-7105.
18. Blagosklonny M.V. J. Natl. Cancer Inst. 2001, 93:239-240.
19. van de Vijver M.J., He Y.D., van't Veer L.J., Dai H., Hart A.A., Voskuil D.W., Schreiber G.J., Peterse J.L., Roberts C., Marton M.J., Parrish M., Atsma D., Witteveen A., Glas A., Delahaye L., van der Velde T., Bartelink H., Rodenhuis S., Rutgers E.T., Friend S.H., Bernards R. N. Engl. J. Med. 2002, 347:1999-2009.
20. van 't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T., Schreiber G.J., Kerkhoven R.M., Roberts C., Linsley P.S., Bernards R., Friend S.H. Nature 2002, 415:530-536.
21. Picard D. Cell Mol. Life Sci. 2002, 59:1640-1648.
22. Stebbins C.E., Russo A.A., Schneider C., Rosen N., Hartl F.U., Pavletich N.P. Cell 1997, 89:239-250.
23. Fukuyo Y., Hunt C.R., Horikoshi N. Cancer Lett. 2010, 290:24-35.
24. Kitson R.R., Chang C.H., Xiong R., Williams H.E., Davis A.L., Lewis W., Dehn D.L., Siegel D., Roe S.M., Prodromou C., Ross D., Moody C.J. Nat. Chem. 2013, 5:307-314.
25. Lu X., Xiao L., Wang L., Ruden D.M. Biochem. Pharmacol. 2012, 83:995-1004.
26. Eccles S.A., Massey A., Raynaud F.I., Sharp S.Y., Box G., Valenti M., Patterson L., de Haven Brandon A., Gowan S., Boxall F., Aherne W., Rowlands M., Hayes A., Martins V., Urban F., Boxall K., Prodromou C., Pearl L., James K., Matthews T.P., Cheung K.M., Kalusa A., Jones K., McDonald E., Barril X., Brough P.A., Cansfield J.E., Dymock B., Drysdale M.J., Finch H., Howes R., Hubbard R.E., Surgenor A., Webb P., Wood M., Wright L., Workman P. Cancer Res. 2008, 68:2850-2860.
27. Siegelin M.D., Habel A., Gaiser T. Neurobiol. Dis. 2009, 33:243-249.
28. Fiskus W., Rao R., Fernandez P., Herger B., Yang Y., Chen J., Kolhe R., Mandawat A., Wang Y., Joshi R., Eaton K., Lee P., Atadja P., Peiper S., Bhalla K. Blood 2008, 112:2896-2905.
29. Okui T., Shimo T., Hassan N.M., Fukazawa T., Kurio N., Takaoka M., Naomoto Y., Sasaki A. Anticancer Res. 2011, 31:1197-1204.
30. Gandhi N., Wild A.T., Chettiar S.T., Aziz K., Kato Y., Gajula R.P., Williams R.D., Cades J.A., Annadanam A., Song D., Zhang Y., Hales R.K., Herman J.M., Armour E., DeWeese T.L., Schaeffer E.M., Tran P.T. Cancer Biol. Ther. 2013, 14:347-356.
31. Zitzmann K., Ailer G., Vlotides G., Spoettl G., Maurer J., Goke B., Beuschlein F., Auernhammer C.J. Int. J. Oncol. 2013, 43:1824-1832.
32. Paraiso K.H., Haarberg H.E., Wood E., Rebecca V.W., Chen Y.A., Xiang Y., Ribas A., Lo R.S., Weber J.S., Sondak V.K., John J.K., Sarnaik A.A., Koomen J.M., Smalley K.S. Clin. Cancer Res. 2012, 18:2502-2514.
33. Saturno G., Valenti M., De Haven Brandon A., Thomas G.V., Eccles S., Clarke P.A., Workman P. Oncotarget 2013, 4:1185-1198.
34. Chaudhary P.M., Eby M., Jasmin A., Bookwalter A., Murray J., Hood L. Immunity 1997, 7:821-830.
35. Li L., Shaw P.E. J. Biol. Chem. 2002, 277:17397-17405.
36. Walker S.R., Nelson E.A., Zou L., Chaudhury M., Signoretti S., Richardson A., Frank D.A. Mol. Cancer Res. 2009, 7:966-976.
37. Berishaj M., Gao S.P., Ahmed S., Leslie K., Al-Ahmadie H., Gerald W.L., Bornmann W., Bromberg J.F. Breast Cancer Res. 2007, 9:R32.
38. Lai S.Y., Childs E.E., Xi S., Coppelli F.M., Gooding W.E., Wells A., Ferris R.L., Grandis J.R. Oncogene 2005, 24:4442-4449.
39. Dorsch M., Danial N.N., Rothman P.B., Goff S.P. Blood 1999, 94:2676-2685.
40. Du W., Hong J., Wang Y.C., Zhang Y.J., Wang P., Su W.Y., Lin Y.W., Lu R., Zou W.P., Xiong H., Fang J.Y. J. Cell. Mol. Med. 2012, 16:1878-1888.
41. Schneider M.R., Hoeflich A., Fischer J.R., Wolf E., Sordat B., Lahm H. Cancer Lett. 2000, 151:31-38.
42. Alvarez J.V., Greulich H., Sellers W.R., Meyerson M., Frank D.A. Cancer Res. 2006, 66:3162-3168.
43. Nilsson C.L., Dillon R., Devakumar A., Shi S.D., Greig M., Rogers J.C., Krastins B., Rosenblatt M., Kilmer G., Major M., Kaboord B.J., Sarracino D., Rezai T., Prakash A., Lopez M., Ji Y., Priebe W., Lang F.F., Colman H., Conrad C.A. J. Proteome Res. 2010, 9:430-443.
44. Giordano C., Vizza D., Panza S., Barone I., Bonofiglio D., Lanzino M., Sisci D., De Amicis F., Fuqua S.A., Catalano S., Ando S. Mol. Oncol. 2013, 7:379-391.
45. Xiong H., Zhang Z.G., Tian X.Q., Sun D.F., Liang Q.C., Zhang Y.J., Lu R., Chen Y.X., Fang J.Y. Neoplasia 2008, 10:287-297.
46. Epling-Burnette P.K., Liu J.H., Catlett-Falcone R., Turkson J., Oshiro M., Kothapalli R., Li Y., Wang J.M., Yang-Yen H.F., Karras J., Jove R., Loughran T.P. J. Clin. Invest. 2001, 107:351-362.
47. Lin Q., Lai R., Chirieac L.R., Li C., Thomazy V.A., Grammatikakis I., Rassidakis G.Z., Zhang W., Fujio Y., Kunisada K., Hamilton S.R., Amin H.M. Am. J. Pathol. 2005, 167:969-980.
48. Peddaboina C., Jupiter D., Fletcher S., Yap J.L., Rai A., Tobin R.P., Jiang W., Rascoe P., Rogers M.K., Smythe W.R., Cao X. BMC Cancer 2012, 12:541.
49. Chen W., Wu J., Shi H., Wang Z., Zhang G., Cao Y., Jiang C., Ding Y. Biomed Res. Int. 2014, 2014:764981.